Ash and Noom Partner to Power At-Home Biomarker Testing for New Microdose GLP-1Rx Program

Ash has deepened its collaboration with Noom as the preventive-health platform launches its new Proactive Health Microdose GLP-1Rx Program—combining personalized GLP-1 microdosing, regular at-home biomarker testing enabled by Ash, and Noom’s behaviour-change coaching model. The partnership aims to help millions track and improve biomarkers most associated with long-term disease risk, reflecting the industry’s growing shift toward proactive, data-driven health.

At the core of the offering is Ash’s operations and testing infrastructure, which handles logistics, device integration, and data quality so Noom can focus on translating biomarker results into personalised interventions. As Kyle Waters, Chief Product Officer at Ash, notes, “The future of longevity depends on seamlessly bridging the digital patient experience with best-in-class physical diagnostic tools. At-home health testing only works at scale when the underlying infrastructure is frictionless and clinically rigorous.”

A central feature of the program is Ash’s device-agnostic architecture, which allows Noom to integrate emerging sample-collection technologies without compromising accuracy or user experience. Noom has incorporated the Tasso+ device into its new biomarker kit—a virtually painless, FDA-cleared blood collection tool designed for users who avoid needles or traditional lancets. User preference data supports its adoption: more than 95% of patients prefer Tasso over legacy methods, and more than 97% say they would use it again.

Noom’s program offers biomarker testing every 16 weeks, giving members a clear view of how foundational labs—such as HbA1c, metabolic panels, and kidney-function markers—shift over time. “We’ve created a fantastic at-home blood testing experience with the Ash platform,” said Aaron Severs, Noom’s Chief Product Officer. “Most Americans are living with suboptimal health today that leads to a higher risk of chronic disease tomorrow. Our new Proactive Health Microdose GLP-1Rx Program includes convenient biomarker testing every 16 weeks so you can see the improvement in your blood.”

The partnership positions Ash as a key infrastructure provider for consumer health platforms seeking clinically robust diagnostics at scale. As the longevity and metabolic-health markets mature, demand for integrated, user-friendly testing solutions is accelerating—moving biomarker-guided care closer to the mainstream.

Click here for the original news story.